As we learn more about diabetes and the huge impacts it can have on patients’ everyday lives, it is almost natural to wonder why treatment has not become easier or safer or perhaps more importantly, more convenient. A massive aspect of medication adherence is the convenience, especially when focusing on diabetes. Most patients do not understand that nonadherence to one diabetes medication however can lead to the addition of more and therefore a further inconvenience to the patient. Patients also understandably dislike the adverse effects that typically accompany diabetes medications, such as hypoglycemia and weight gain. Hopefully, a new drug may be able to diminish this growing issue.
IDegLira is an injectable diabetes management medication that is a combination of basal insulin and GLP-1RA, or liraglutide. The medication is injected once daily and tackles two different physiological deficits in patients with type 2 diabetes. The basal insulin reduces fasting blood glucose while the GLP-1RA keeps postprandial glucose values under control. A study with patients already on basal insulin was completed to see if adding insulin aspart or liraglutide would control their glucose levels better. The addition of liraglutide was recorded to be more effective as well as less hindering, as it had lower rates of hypoglycemia and weight loss in patients as opposed to weight gain.
Positive results have been seen in several clinical trials involving the combination drug of insulin basal and GLP-1RA. Hopefully this more convenient, effective, and safe medication will come out on the market soon to aid those with type 2 diabetes.
Do you think patients would truly be more adherent to this medication, a single injection, than metformin, a single oral tablet per day? Even if this is more effective, will patients choose an injection over a pill?
Reference: Hughes E. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes. Primary Care Diabetes. Article in Press. https://www-clinicalkey-com.pitt.idm.oclc.org/#!/content/journal/1-s2.0-S1751991815001837